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Abstract Background: Fidaxomicin is a macrocyclic antibiotic approved in 2011 by the
US Food and Drug Administration for treatment of Clostridium difficile-
associated diarrhoea (CDAD).
Objective: Herein, we present an epidemiological method to estimate, on a
case mix basis, and from the perspective of the US health system, the war-
ranted (justifiable) price per day for fidaxomicin, as a percent of the wholesale
acquisition cost (WAC) per day for fidaxomicin ($US280).
Methods: Data from two randomized controlled studies (Optimer-003
[n = 596] and Optimer-004 [n = 509]) were used to discern the number-needed-
to-treat (NNT = 7.1) for sustained clinical response. Sustained clinical res-
ponse was defined as clinical response at the end of treatment, and survival
without proven or suspected CDAD recurrence through 25 days beyond
the end of treatment. National data for primary and secondary cases (the case
mix) of CDAD (mean hospital length of stay [LOS], and mean cost) were
derived from the 2009 US Healthcare Cost and Utilization Project. The
method for attribution of hospital LOS for secondary cases of CDAD was
derived from a study published by O’Brien et al. in 2007. Comparative regi-
mens of vancomycin were: (i) injectable used orally, 125mg four times daily
(qid; WAC of $US6/day), with use of vancomycin hydrochloride (HCl) cap-
sules, 125mg qid (WAC of $US106/day) post-hospital discharge; (ii) vanco-
mycin HCl capsules, 125mg qid; and (iii) vancomycin HCl capsules, 250mg
qid (WAC of $US196/day). Findings are expressed in 2011 US dollars. The
study perspective is that of the US health system.
Results: The warranted price per day for fidaxomicin represented 95% of the
WAC per day for fidaxomicin compared with use of injectable vancomycin
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(orally) 125mg qid (with subsequent use of vancomycin HCl capsules, 125mg
qid post-hospital discharge); 109% of the WAC per day for fidaxomicin
compared with use of vancomycin HCl capsules, 125mg qid; and 141% of the
WAC per day for fidaxomicin when compared with use of vancomycin HCl
capsules, 250mg qid.
Conclusion: From the perspective of the US health system, fidaxomicin re-
presents value for money in the treatment of CDAD. The methodology em-
ployed in this research has application beyond antimicrobial pharmacotherapy.
Introduction
Clostridium difficile is a Gram-positive, spore-
forming, toxin-producing anaerobic bacillus. It is
the most common cause of infectious diarrhoea
in hospitalized patients in North America and
Europe, where both the incidence and severity of
the disease have increased significantly since
2000.[1] Debate persists as to the effect of the
emergence of a hyper-virulent C. difficile strain,
denoted as NAP1/BI/027 (North American Pulsed
Field type 1 [NAP1], restriction-endonuclease anal-
ysis [REA] type BI, or polymersase-chain-reaction
biotype 027; collectively referred to as NAP1/
BI/0270), on the observed increase in both the
incidence and severity of disease.[1] That said,
mortality due to C. difficile-associated diarrhoea
(CDAD) has increased significantly over the past
decade.[1,2]
At present it is estimated that NAP1/BI/027
C. difficile is present in approximately one-third
of cases.[1,2] However, standard hospital laboratory
procedure is to test for the presence of C. difficile
toxin in a faecal sample prior to initiating phar-
macotherapy; however, restriction-endonuclease
strain typing is rarely, if ever, conducted.[3]
Guidelines published in 2010 from the Infec-
tious Disease Society of America, and the Society
for Healthcare Epidemiology of America, prior-
itize the usage of metronidazole or vancomycin
for CDAD, depending upon disease severity.[4]
Fidaxomicin (Dificid, Optimer Pharmaceu-
ticals, Inc., San Diego, CA, USA), a macrocyclic
antibiotic approved in 2011 by the US Food and
Drug Administration (FDA) for use in the treat-
ment of C. difficile infection, is more active in vitro
than vancomycin by a factor of approximately
eight.[1] Recent clinical trials indicate fidaxomicin is
superior to vancomycin in terms of rate of recur-
rence of CDAD, and rate of global cure in patients
infected with strains other than NAP1/BI/027 (i.e.
Non-NAP1/BI/027).[1,5]
Internationally, payers are increasingly man-
dating the demonstration of value for money with
regard to pharmacotherapy.[6] Given the inability
of clinicians to distinguish – for a given patient
with infection – the strain of C. difficile respon-
sible for the infection, as restriction-endonuclease
strain typing is rarely, if ever, conducted, this in-
quiry utilized a novel epidemiological approach
to estimate whether the market price for fidax-
omicin is warranted (justifiable) from the per-
spective of the US health system.
Methods
The number-needed-to-treat (NNT), the re-
ciprocal of the absolute-risk-reduction (ARR),
is a practical evidence-based indicator denoting
the number of persons requiring treatment (i.e.
intervention) to prevent the occurrence of one un-
desirable (adverse) outcome, relative to that which
would have been observed with use of an alternative
(comparator) treatment, or standard care.[7]
Comparative data regarding the efficacy of
fidaxomicin in the treatment of CDAD were de-
rived from two pivotal randomized controlled
trials (Optimer-003 [n = 596], and Optimer-004
[n = 509], Optimer Pharmaceuticals, Inc.).[5] The
regimens employed in the two randomized clin-
ical trials were 10 days’ treatment with either
fidaxomicin 200mg twice daily (bid; wholesale
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acquisition cost [WAC1] of $US280/day), or
vancomycin hydrochloride (HCl) 125mg four
times daily (qid; WAC of $US106/day).
The pooled NNT for sustained clinical response
was 7.1 (Wilson score method).[8] Sustained clin-
ical response was defined as clinical response at
the end of treatment, and survival without proven
or suspected CDAD recurrence through 25 days
beyond the end of treatment. Based on the pooled
NNT, for every seven patients2 treated with fi-
daxomicin, there was avoidance of one hospital
readmission for CDAD, as compared with use of
vancomycin.
In the present study, the comparative regi-
mens of vancomycin were: (i) injectable admin-
istered orally, 125mg qid (WAC of $US6/day);3
(ii) vancomycin HCl capsules, 125mg qid (WAC
of $US106/day); and (iii) vancomycin HCl cap-
sules, 250mg qid (WAC of $US196/day) [values
are expressed in 2011 US dollars].
Hospital Perspective
National (US) data for primary and secondary
cases of CDAD (International Classification of
Diseases, 9th Revision, Clinical Modification
[ICD-9-CM] code 008.45) were derived from the
2009 US Healthcare Cost and Utilization Project
(HCUP).[9,10] Data contained in each discharge
summary pertinent to this study included patient
demographics, expected source of primary pay-
ment, the diagnostic profile based on ICD-9-CM
coding, measures of resource use, including mean
hospital length of stay (LOS), and mean hospital
cost,4 and disposition of the patient upon dis-
charge, including mortality.
The attribution of hospital LOS and hospital
cost in secondary cases of CDAD was based on
the methodology advanced by O’Brien et al.[11]
Specifically, in secondary cases of CDAD, 18% of
hospital LOS and 46% of hospital cost is attri-
butable directly to CDAD. All findings stemming
from this inquiry are expressed in 2011 dollars.5
For both primary and secondary cases of
CDAD, and for each comparative regimen of
vancomycin examined, the following equationwas
derived to discern, on a per-day basis, whether
there existed a savings or loss (dollar value) net
the market price (WAC) of fidaxomicin in the
hospital (inpatient) environment:
p1¼ l=NNT
 þ gdLOSð Þ =LOS  $US280:00 
(Eq: 1Þ
where,
p1 = estimate of savings or loss net the market
price (WAC) for fidaxomicin on a per-day basis
in the hospital;
l=mean hospital cost (2011 dollars) for either
a primary or secondary case of CDAD;
LOS =hospital LOS for a primary or second-
ary case of CDAD;
g = cost of vancomycin (alternative pharma-
cotherapy regimen) for a primary or secondary
case of CDAD for the hospital LOS;
$US280 =market price (WAC) of fidaxomicin
on a per-day basis.
In this inquiry, it is assumed that the initiation
of antimicrobial pharmacotherapy commenced
on day one of the hospital LOS in all primary
cases of CDAD, and for all of the attributable
hospital LOS in secondary cases of CDAD. The
aforementioned assumption established the most
rigorous (conservative) threshold for the depen-
dent variable p1 in equation 1 to surmount (i.e.
result in a savings [dollar value]).
Ambulatory Perspective
Upon hospital discharge, it is assumed pa-
tients with either a primary or a secondary case of
CDAD were prescribed pharmacotherapy for the
1 WACs for pharmacotherapy referenced in this inquiry were obtained from First Data Bank.
2 This analysis utilized a pooled NNT and hospital length of stay rounded to an integer.
3 Assumed use of vancomycin HCl capsules, 125mg qid, for ambulatory duration of treatment.
4 Hospital costs, not charges, for ICD-9-CM code 008.45 were discerned from the 2009 HCUP Nationwide
Inpatient Sample (NIS).
5 Inflation adjustment to 2011 dollars via US Bureau of Labor Statistics <http://www.bls.gov/data/inflation_
calculator.htm>.
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balance of a 10-day regimen, barring mortality
during the LOS. For both primary and secondary
cases of CDAD, and for each comparative regi-
men of vancomycin examined, the following equa-
tion was derived to discern, on a per-day basis,
whether there existed a savings or loss (dollar
value) with use of fidaxomicin in the ambulatory
(outpatient) environment:
p2¼ gFð Þ (Eq: 2Þ
where,
p2 = estimate of savings or loss for a primary or
secondary case of CDAD, on a per-day basis, in
the ambulatory environment;
g = cost of vancomycin (alternative pharma-
cotherapy regimen) for a primary or secondary
case of CDAD on a per-day basis;
F =market price (WAC) of fidaxomicin for a
primary or secondary case of CDAD on a per-
day basis.
Health System Perspective
For both primary and secondary cases of
CDAD, and for each comparative regimen of
vancomycin examined, the following equation
was derived to discern whether there existed a
savings or loss (dollar value) with use of fidax-
omicin from the perspective of the US health
system:
P¼ p3  p4 (Eq: 3Þ
where,
P = estimate of US health system savings or
loss with use of fidaxomicin;
p3 = total savings or loss, for a primary or sec-
ondary case of CDAD, based on days of phar-
macotherapy in the hospital;
p4 = total savings or loss, for a primary or sec-
ondary case of CDAD, based on days of phar-
macotherapy in the ambulatory environment.
Warranted Price for Fidaxomicin
The following equation utilized the above-
referenced calculation of savings or loss (dollar
value) at the hospital and ambulatory levels, for
both primary and secondary cases of CDAD, and
for each comparative regimen of vancomycin
examined, to discern the warranted price of fi-
daxomicin on a per-day basis:
h¼ $US280 D (Eq: 4Þ
where,
h =warranted price for fidaxomicin at the
hospital or ambulatory level;
$US280 =WAC per day for a regimen of
fidaxomicin;
D = savings or loss (dollar value) at the hospital
or ambulatory level, for both primary and sec-
ondary cases of CDAD, and for each compara-
tive regimen of vancomycin examined, on a per-day
basis.
In both primary and secondary cases of
CDAD, the warranted price for fidaxomicin on
a per-day basis, from the perspective of the US
health system, is the weighted average of the
warranted price per day, as discerned at the hos-
pital and ambulatory levels, respectively, and for
a given combination of hospital LOS and ambu-
latory duration. In turn, we report the warranted
price per day for fidaxomicin, from the perspec-
tive of the US health system, as a percent of the
WAC per day for fidaxomicin.
Finally, the warranted price per day for fi-
daxomicin, from the perspective of the US health
system, as a percent of the WAC per day for fi-
daxomicin, in both primary and secondary cases
of CDAD, is weighted by the case mix for CDAD
(primary or secondary) in 2009, in order to yield
an aggregate appraisal (from the perspective of
the US health system) of the warranted price per
day for fidaxomicin, as a percent of the WAC per
day for fidaxomicin.
Results
In 2009, there were 336 565 hospitalizations
wherein CDAD (ICD-9-CM code 008.45) was
recorded in the discharge summary, with 110 553
discharge summaries reporting CDAD as the
primary diagnosis. For the 336 565 hospitaliza-
tions wherein CDAD was recorded in the dis-
charge summary, 65%were >65 years of age, 57%
were female, and 68% of discharges were paid by
Medicare as the primary insurance carrier. Of
the 110 553 hospitalizations wherein CDAD was
recorded in the discharge summary as the pri-
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mary diagnosis, 67% were >65 years of age, 64%
were female, 69% of discharges were paid by
Medicare as the primary insurance carrier, and
the mortality rate was 3.7%. Of the 226 408 hos-
pitalizations wherein CDAD was recorded in the
discharge summary as a secondary diagnosis,
64%were >65 years of age, 54%were female, 67%
of discharges were paid by Medicare as the pri-
mary insurance carrier, and the mortality rate
was 11.7%.6
The mean – standard error (SE) hospital LOS
for a primary case of CDAD in 2009 was 6.9
days– 0.1, with a mean hospital cost of $US10644
(2011 dollars). The mean hospital LOS for a pa-
tient with a secondary case of CDAD was 15.9
days – 0.1, with an attributed LOS due to CDAD
of 2.9 days. The mean hospital cost for a patient
with a secondary case of CDAD was $US34 260,
with an attributed hospital cost due to CDAD of
$US15 759.
Table I presents the savings or loss (dollar
value) per day with use of fidaxomicin as com-
pared with vancomycin for primary cases of
CDAD, the warranted price per day for fidax-
omicin from a hospital, ambulatory and health
system perspective, and the warranted price per
day for fidaxomicin, from the perspective of the
US health system, as a percent of the WAC per
day for fidaxomicin. Results indicate that the
warranted price per day for fidaxomicin, from the
perspective of the US health system, represents
67% of the WAC per day for fidaxomicin when
compared with use of injectable vancomycin
125mg qid administered orally (with subsequent
use of vancomycin HCl capsules, 125mg qid in
the ambulatory environment), 92% of the WAC
per day for fidaxomicin when compared with use
of vancomycin HCl capsules, 125mg qid, and
124% of the WAC per day for fidaxomicin when
compared with use of vancomycin HCl capsules,
250mg qid.
The savings or loss (dollar value) per day with
use of fidaxomicin as compared with vancomycin
for secondary cases of CDAD, the warranted
price per day for fidaxomicin from a hospital,
ambulatory and health system perspective, and
the warranted price per day for fidaxomicin, from
the perspective of the US health system, as a per-
cent of the WAC per day for fidaxomicin are
presented in table II. Results indicate that the
warranted price per day for fidaxomicin, from the
perspective of the US health system, represents
108% of the WAC per day for fidaxomicin when
compared with use of injectable vancomycin
125mg qid administered orally (with subsequent
use of vancomycin HCl capsules, 125mg qid in
the ambulatory environment), 118% of the WAC
per day for fidaxomicin when compared with use
Table I. Primary cases of Clostridium difficile-associated diarrhoea
(CDAD): savings or loss per day ($US) [hospital and ambulatory],
and in total (US health system) with use of fidaxomicin (FDX) as
compared with vancomycin, warranted price per day for FDX from a
hospital, ambulatory and US health system perspective, and the
warranted price per day for FDX, from the perspective of the US
health system, as a percent of the wholesale acquisition cost (WAC)
per day for FDX
Primary cases
of CDAD








Savings or loss by perspective
Hospital (7 days) -56.37/day +43.63/day +133.63/day
Ambulatory (3 days) -174.00/dayb -174.00/day -84.00/day
Health system -916.57/day -216.57/day +683.43/day
Warranted price for FDX by perspective
Hospital (7 days) +223.63/day +323.63/day +414.63/day









a Cost of comparative regimens of vancomycin: (i) injectable used
orally, 125mg qid (WAC of $US6/day); (ii) vancomycin hydro-
chloride (HCl) capsules, 125mg qid (WAC of $US106/day); and
(iii) vancomycin HCl capsules, 250mg qid (WAC of $US196/day).
b Assumed use of vancomycin capsules, 125mg qid, for ambula-
tory duration of treatment.
c Cost of fidaxomicin: 200mg bid (WAC of $US280/day).
admin. = administration; bid = twice daily; qid = four times daily.
6 Primary and secondary cases of CDAD (ICD-9-CM code 008.45) do not add to the aggregate number of
CDAD cases reported in theUS in 2009, due to weightings employed in the HCUPNIS, and the resulting standard
error (SE) for each mean. Estimated percentage of primary cases= 32.8%; estimated percentage of secondary
cases= 67.2%.
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of vancomycin HCl capsules, 125mg qid, and
150% of the WAC per day for fidaxomicin when
compared with use of vancomycin HCl capsules,
250mg qid.
Table III details the warranted price per day
for fidaxomicin, from the perspective of the US
health system, as a percent of the WAC per day
for fidaxomicin, having accounted for the case
mix for CDAD (primary or secondary) in 2009.
Results indicate that on a case mix basis, the
warranted price per day for fidaxomicin, from the
perspective of the US health system, represents
95% of the WAC per day for fidaxomicin when
compared with use of injectable vancomycin
125mg qid administered orally (with subsequent
use of vancomycin HCl capsules, 125mg qid in
the ambulatory environment), 109% of the WAC
per day for fidaxomicin when compared with use
of vancomycin HCl capsules, 125mg qid, and
141% of the WAC per day for fidaxomicin when
compared with use of vancomycin HCl capsules,
250mg qid.
Discussion
Comparative effectiveness research (CER), as
defined by the US Agency for Healthcare Re-
search and Quality (AHRQ), is to be designed to
inform stakeholders of the clinical and/or economic
benefit(s) of competing alternatives.[12] This in-
quiry utilized a novel epidemiological method to
estimate, on a case mix basis, and from the per-
spective of the US health system, the warranted
price per day for fidaxomicin, as a percent of the
WAC per day for fidaxomicin. Findings ranged
from 95% to 141% across the alternative regimens
of vancomycin examined. These results, coupled
with recent evidence indicating fidaxomicin is
significantly more effective than vancomycin in
achieving clinical cure for CDAD in the presence
of concomitant antimicrobial pharmacotherapy,
and in preventing recurrence of disease, under-
scores the clinical and economic benefits to be
ascribed to fidaxomicin.[13]
Table II. Secondary cases of Clostridium difficile-associated diar-
rhoea (CDAD): savings or loss per day ($US) [hospital and ambula-
tory], and in total (US health system) with use of fidaxomicin (FDX) as
compared with vancomycin, warranted price per day for FDX from a
hospital, ambulatory and US health system perspective, and the
warranted price per day for FDX, from the perspective of the US
health system, as a percent of the wholesale acquisition cost (WAC)
per day for FDX
Secondary cases
of CDAD








Savings or loss by perspective
Hospital (3 days) +476.43/day +576.43/day +666.43/day
Ambulatory (7 days) -174.00/dayb -174.00/day -84.00/day
Health system +211.29/day +511.29/day +1411.29/day
Warranted price for fidaxomicin by perspective
Hospital (3 days) +756.43/day +856.43/day +946.43/day









a Cost of comparative regimens of vancomycin: (i) injectable used
orally, 125mg qid (WAC of $US6/day); (ii) vancomycin hydro-
chloride (HCl) capsules, 125mg qid (WAC of $US106/day); and
(iii) vancomycin HCl capsules, 250mg qid (WAC of $US196/day).
b Assumed use of vancomycin capsules, 125mg qid, for ambula-
tory duration of treatment.
c Cost of FDX: 200mg bid (WAC of $US280/day).
admin. = administration; bid = twice daily; qid = four times daily.
Table III. Primary and secondary cases of Clostridium difficile-
associated diarrhoea (CDAD): the warranted price per day ($US) for
fidaxomicin (FDX), from the perspective of the US health system, as
a percent of the wholesale acquisition cost (WAC) per day for FDX,a
weighted by the US case mix (primary and secondary) for CDAD in
2009b








Percent of WAC 95d 109 141
a Cost of FDX: 200mg bid (WAC of $US280/day).
b Primary and secondary cases of CDAD do not add to the ag-
gregate number of CDAD cases reported in the US in 2009, due
to weightings employed in the US Healthcare Cost and Utilization
Project Nationwide Inpatient Sample, and resulting standard
error for each mean. Estimated percentage of primary cases
= 32.8%; estimated percentage of secondary cases =67.2%.
c Cost of comparative regimens of vancomycin: (i) injectable used
orally, 125mg qid (WAC of $US6/day); (ii) vancomycin hydro-
chloride (HCl) capsules, 125mg qid (WAC of $US106/day); and
(iii) vancomycin HCl capsules, 250mg qid (WAC of $US196/day).
d Assumed use of vancomycin capsules, 125mg qid, for ambula-
tory duration of treatment.
admin. = administration; bid = twice daily; qid = four times daily.
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We note that among primary cases of CDAD,
the warranted price per day for fidaxomicin, from
the perspective of the US health system, represents
67% of the WAC per day for fidaxomicin when
compared with use of injectable vancomycin
125mg qid administered orally (with subsequent
use of vancomycin HCl capsules, 125mg qid in
the ambulatory environment). We hypothesize
that the majority of primary cases of CDAD are
due to recurrence of disease, and that use of fi-
daxomicin will reduce the proportion of primary
cases annually. Thus, there exists the potential for
the warranted price per day for fidaxomicin, from
the perspective of the US health system, to in-
crease from the present estimate of 95% of the
WAC per day for fidaxomicin to that of parity
(i.e. ‡100% of the WAC per day for fidaxomicin)
when compared with use of injectable vancomycin
125mg qid administered orally (with subsequent
use of vancomycin HCl capsules, 125mg qid, in
the ambulatory environment).
Health service substitution effects have been
observed across the components of the US health
system, and in the treatment of a wide range of
disease states.[14,15] Our findings indicate that for
the ambulatory (outpatient) duration of the
treatment regimen, use of fidaxomicin results in a
loss (dollar value) on a per-day basis relative to
each of the comparative regimens of vancomycin
examined, and that the warranted price per day
for fidaxomicin, as a percent of the WAC per day
for fidaxomicin, was far less than the threshold
value of $US280 per day. However, in the majority
of primary-case scenarios, and in all secondary-case
scenarios of CDAD examined, use of fidaxomicin
during the hospital duration of the treatment re-
gimen resulted in a savings (dollar value) on a
per-day basis relative to each of the comparative
regimens of vancomycin examined, and the war-
ranted price per day for fidaxomicin exceeded
the threshold value of $US280 per day. Thus, the
offset potential between the hospital and ambu-
latory components of care were observed in the
findings for the US health system. Stakeholders
need to recognize that a loss (dollar value) – from
an accounting perspective – in one component of
the US health system may not connote a loss to
the enterprise in the aggregate.
This research is constrained by the nature of
the USHCUPNIS, as data are not collected as to
the day pharmacotherapy is initiated within a
given hospital LOS. That said, our assumption
that the initiation of antimicrobial pharma-
cotherapy commenced on day one of the hospital
LOS in all primary cases of CDAD, and for all of
the attributable hospital LOS in secondary cases
of CDAD, established the most rigorous (con-
servative) threshold for the dependent variable p1
in equation 1 to surmount (i.e. result in a savings
[dollar value]). Finally, as restriction-endonuclease
strain typing is rarely, if ever, conducted, we were
unable to account for the magnitude of the in-
cidence of the hyper-virulent C. difficile strain
NAP1/BI/027, and the resulting effect on the
efficacy of fidaxomicin.
Conclusion
The incidence, severity, mortality and expen-
ditures associated with CDAD have increased
significantly over the past decade. From the per-
spective of the US health system, fidaxomicin
represents value for money in the treatment of
CDAD. Future prospective research is required
to confirm the findings presented herein. The
epidemiologically-basedmethod employed in this
research has application beyond the evaluation of
antimicrobial pharmacotherapy for the treat-
ment of CDAD.
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